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Oral Presentations S185was observed in one patient. The overall survival of these patients
was 94% with a median follow up of 2.8 years (range, 0.2-12 years).
The causes of death were infection and complications of aGVHD.
These results demonstrate the usefulness of using HSCT in the
non-SCID population and absence of an MRD should not delay
HSCT. We conclude that HSCT should be considered early and
prior to the onset of significant morbidity in non-SCID PIDs.85
IMPROVED CLINICAL OUTCOME OF HIGH RISK b THALASSEMIA MAJOR
PATIENTS UNDER GOING A HLA MATCHED RELATED ALLOGENEIC
STEM CELL TRANSPLANT WITH THE USE OF A TREOSULPHAN BASED
CONDITIONING REGIMEN
Mathews, V., George, B., Lakshmi, K.M., Abraham, A., Ahmed, R.,
Viswabandya, A., Srivastava, A. Christian Medical College, Vellore,
Tamil Nadu, India
The clinical outcome post allogeneic SCT in patients with b thal-
assemia major (TM) who belong to the Class III and the Class III
high risk group (defined by us previously; BBMT 2007;13:889),
remains poor.
From August 2009 we used a Treosulphan based conditioning
regimen (thiotepa: 8 mg/kg on day-6, treosulphan: 14gm/m2 for 3
days from day -5 to -3 and fludarabine 40mg/m2 for 4 days from
day -5 to -2) in an effort to improve the clinical outcome in these sub-
sets. 18 patients have since then had this conditioning regimen at our
center. The median age was 10 years (range: 2 – 17) and the median
liver size was 6 cm (range: 2-10). 15 (83.3%) were Class III while 10
(55%) wereClass III high risk (age$ 7 years and liver size$ 5cms). 3
were HCV positive, 2 were having a second SCT and 4 patients had
a prior splenectomy. All patients had HLA identical related donors.
Bone marrow was the source of stem cells in 14 (77%) while the rest
had PBSC. Themedian TNCdose was 3.95x108/kg (range: 2.5-8.4).
All 18 patients engrafted (ANC . 500/mm3) at a median of 17 days
(range: 11 – 22). Features suggestive of a SOSwere seen in 4 patients,
of whom 2 subsequently died on day 41 and 44 respectively (second-
ary to sepsis and multi-organ failure). In 7 patients there was tran-
sient hypoxia, the etiology of which could not be explained by
routine tests and imaging. DAH occurred in 4 of these cases and 2
of them (who also had features of SOS) succumbed to subsequent
complications. Besides the two deaths an additional patient has had
secondary graft failure on day 76 (with autologous recovery). Of
the remaining 15 patients a day 28 chimerism (VNTR assay) study
revealed complete chimerism in 10 (66%) while 4 had donor chime-
rism over 90% and over the next fewmonths improved further (none
require blood transfusions). 4 (27%) of the 15 patient who could be
evaluated developed acute GVHD which was grade III/IV in one
case. In comparison to our previously reported data among the entire
Class III and the Class III high risk subset who had an EFS of
70.366% and 2467% respectively (BBMT 2007), these results are
a significant improvement.
In conclusion a treosulphan based conditioning regimen is well
tolerated in high risk patients with TM. While the incidence of
SOS is very low compared to that seen with a conventional busul-
phan based regimen there remains some concern about the high in-
cidence of pulmonary complications that was noted in this cohort.86
RISK STRATIFICATION WITHOUT A LIVER BIOPSY OF PATIENTS WITH
b THALASSEMIA MAJOR UNDER GOING A MATCHED RELATED ALLOGE-
NEIC BONE MARROW TRANSPLANT
Mathews, V., Lakshmi, K.M., Abraham, A., Ahmed, R.,
Viswabandya, A., George, B., Srivastava, A. Christian Medical College,
Vellore, TN, India
Conventional risk stratification of patients with b thalassemia ma-
jor (TM) prior to an allogeneic SCT requires a liver biopsy. 288 pa-
tients with TM underwent a SCT at our center. The median age was
7 years (range: 2-24). By the conventional risk stratification, 14
(4.9%)wereClass I while 142 (49.3%)wereClass III.Myelo-ablative
conditioning regimen in the majority was busulphan based (oral).
284 (98.6%) received a bone marrow graft. At a median follow up
of 49 months (range: 2-213) the 5 year Kaplan-Meir estimate ofoverall survival (OS) and event free survival (EFS) was 71.362.8%
and 64.762.9% respectively. On a univariate analysis factors associ-
ated with an adverse impact on EFS were patients’ age, donor age,
liver size, serum AST level, serum ferritin level, palpable spleen
and splenectomy. On a multivariate analysis only liver size retained
its significant adverse impact. Since the majority of our patients be-
longed to Class III and we had earlier shown that age $ 7 years and
liver size$ 5 cms had a significant adverse impact in this group, even
on a multivariate analysis (BBMT 2007) we used these numbers to
dichotomize the group. Of the remaining factors that had an adverse
impact on EFS, donor age (significant correlation with recipient age)
and splenectomy (small number) were excluded. The median values
of the serumAST ($ 50U/Lt) and ferritin ($ 3000mg/Lt) levels were
then also used to dichotomise the group. On a cox-regression anal-
ysis liver size $ 5cms (RR 5 2.8; P 5 0.000), age $ 7 years (RR 5
2; P 5 0.004), serum ferritin $ 3000mg/Lt (RR 5 1.6; P 5 0.029)
and a palpable spleen (included those that had splenectomy) (RR
5 2.2; P 5 0.004) were significant. Scores were generated for each
of the above adverse factors proportional to the relative risk as illus-
trated in Table 1. The total score could therefore range form 0 to 9
for each patient. Kaplan-Meir estimates of EFS were generated for
each of these scores and clustered into groups. Three groups could
be recognized; Group A with a score # 2 (n 5 121 [42%]), Group
B 5 . 2 to \ 9 (n 5 118 [41%]) and Group C 5 9 (n 5 48
[17%]). Kaplan-Meir estimates of EFS and cumulative risk of rejec-
tion between these groups was significantly different (P5 0.000 and
0.007 respectively)
The proposed risk stratification does not require a liver biopsy, has
a good distribution of cases in the defined groups and better
identifies a high risk subset of patients than the conventional risk
stratification system.
Table 1. Scoring systemVariable/Score 0 2 3
Liver Size (cm) <5 $ 5
Age (years) <7 $ 7
Serum Ferrtin (mg/Lt) <3000 $ 3000
Spleen palpable No Yes/Post splenectomy87
DIFFERENTIAL IMPACT OF HLA-A, -B, AND -DRB1 MISMATCHING IN RE-
LATION TO OTHER VARIABLES ON THE OUTCOMES OF MYELOABLATIVE
UNRELATED SINGLE DONOR UMBILICAL CORD BLOOD TRANSPLANTA-
TION FROM 4/6 MATCHED UNITS IN CHILDREN AND YOUNG ADULTS
Prasad, V.K.1, Mendizabal, A.2, Tewari, P.1, Page, K.1, Parikh, S.H.1,
Szabolcs, P.1, Driscoll, T.A.1, Martin, P.L.1, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2The EMMES Corporation,
Rockville, MD
Background: Use of 4/6 matched cord blood units (CBU) substan-
tially expands the chances of finding a suitable donor for patients
lacking an adult match. An understanding of the impact of locus-spe-
cific HLA mismatching, cellular characteristics of CBU and other
variables will help optimize CBU selection and further improve out-
comes of 4/6 unrelated cord blood transplant (UCBT).
Methods: All recipients (age # 21yrs) of myeloablative UCBT be-
tween 08/1993 and 11/2007 at Duke from single 4/6 matched
(low-res HLA-A and B; high-res DRB1) CBU were studied (median
follow-up 6.9 years; range, 0.9-15.1). Of 314 patients (median age 6.1
years; range 0.1-20.3), 63% were male, 27% non-Caucasian, 38%
CMV positive, and 61% transplated for malignancy. Statistics in-
cluded Kaplan-Meier (KM), log-rank, and Cox models. Prognostic
factors were assessed in univariate KM analyses of overall survival
(OS) and cumulative incidence (C_Inc) of engraftment and
GVHD. Cox proportional hazards models were constructed using
stepwise selection. P-values\ 0.05 were statistically significant in
multivariate model. Median (range)/kg of cryopreserved TNC, rein-
fused TNC, CD34, and CFU doses were 6.2(0.9-38.2)x107, 4.8(0.5-
27.4)x107, 1.8(0.02-105)x105, and 3.6(0-50)x104, respectively.
RESULTS: Primary graft failure and autologous recovery occurred
in 21 (6.7%) and 10 (3.2%). C_Inc of grades III-IV acuteGVHDand
chronic GVHD at 1 year was 13.6%(95%CI, 9.8%-17.4%) and
13.9%(95%CI, 9.9%-17.9%). OS at 1 year and 3 years were
54.8%(95%CI, 49.1%-60.1%) and 47.5%(95%CI, 41.8%-52.9%),
S186 Oral Presentationsrespectively. In multivariate model, 1-year and long-term OS were
better in boys (p 5 0.024) and patients receiving a pre-cryo TNC
. 2.5x107/kg (p 5 0.0002). In patients with malignancies, higher
HLA-B mismatching (2 vs. 0 or 1) and in non-malignancy patients,
higher HLA-DRB1 mismatching (1 vs. 0) led to worse OS (table).
HLA-A mismatching (1 vs. 0) had no impact. OS in minority and
Caucasian patients were similar. Probability of malignancy relapse
at 5 yrs was 10.1%(95%CI 5.8%-14.4%).
Table 1. Overall Survival: Significant Factors in Multivariate
Analysis
All patients Hazard Ratio (95% CI) p - valuePre-Cryo TNC < or 5 2.5x10e7/kg 1.000
Pre-Cryo TNC > 2.5x10e7/kg 0.415 (0.26-0.66) 0.0002
Recipient Sex: Male 1.000
Recipient Sex: Female 1.431 (1.05-1.95) 0.0241
Malignant Diagnoses
Recipient CMV Negative 1.000
Recipient CMV Positive 1.482 (1.02-2.16) 0.04
0 or 1 HLA-B Mismatch 1.000
2 HLA-B Mismatches 2.832 (1.24-6.49) 0.0139
Non-Malignant Diagnoses
Pre-Cryo TNC < or 5 8.6x10e7/kg 1.000
Pre-Cryo TNC > 8.6x10e7/kg 0.570 (0.34-0.96) 0.0354
No HLA-DRB1 Mismatch 1.000
1 HLA-DRB1 Mismatch 1.732 (1.02-2.93) 0.0412CONCLUSIONS: 4/6 matched UCBT is effective and carries low
probabilities of graft failure, acute GVHD (III-IV) and chronic
GVHD in children and young patients. These outcomes are similar
to those reported with better matched UCB grafts and support the
use of 4/6 UCBT for patients lacking other donors. HLA-A, -B
and -DRB1 mismatching has differential outcome on OS. Further
studies will help in utilizing these differences to optimize CBU
selection.88
PRELIMINARY RESULTS OF PHASE I/II STUDY OF CLOFARABINE (CLO) IN
COMBINATION WITH CYTARABINE AND TOTAL BODY IRRADIATION
(TBI) FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION
(ALLOSCT) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS (CAYA)
WITH POOR-RISK ACUTE LEUKEMIA
Ricci, A.M.1, Geyer, M.B.1, Harrison, L.A.1, Duffy, D.1, Bhatia, M.1,
Garvin, J.H.1, George, D.1, Satwani, P.1, Cheerva, A.C.2, Talano, J.3,
Ozkaynak, M.F.4, Moore, T.B.5, Schwartz, J.6, Baxter-Lowe, L.A.7,
Cairo, M.S.1,6,8 1Columbia University, New York, NY; 2University of
Louisville, Louisville, KY; 3Medical College of Wisconsin, Milwaukee,
WI; 4New York Medical College, New York, NY; 5University of Califor-
nia Los Angeles, Los Angeles, CA; 6Columbia University, New York, NY;
7University of California San Francisco, San Francisco, CA; 8Columbia
University, New York, NY
Background:CAYA with ALL or AML in third complete remission
(CR3), refractory relapse (RR) or induction failure (IF) continue to
have extremely poor prognosis,\ 20% EFS (Gaynon, BJH, 2005,
Wells et al, JCO, 2003). CLO is an inhibitor of DNA polymerase
and ribonucleotide reductase and has demonstrated activity in
CAYAwith relapsed ALL/AML (Jeha et al., JCO, 2006, 2009). Stud-
ies suggest synergy with cytarabine (Faderl et al, Blood, 2005). CLO
with cytarabine has shown greater rates of CR than CLO alone in
adults with AML and in CAYA with relapsed ALL/ AML (Faderl
et al, Blood, 2006, 2008; Cooper et al, ASH, 2009).We sought to de-
termine maximum tolerated dose (MTD) or tolerable dose of CLO
and assess the safety, progression-free survival (PFS) and overall sur-
vival (OS) of CLO, cytarabine and TBI followed by AlloSCT in
CAYA with poor-risk ALL/ AML.
Methods: This is a multi-center phase I/II trial of novel condition-
ing regimen of CLO (dose escalation: 40mg/m2 [n 5 3], 46 mg/m2
[n 5 3], 52 mg/m2 [n 5 8]) x5d, sequential (4 hrs later) cytarabine
1000 mg/m2 x6d and TBI (1200cGy) followed by AlloSCT from
matched related or unrelated donors in CAYA with ALL/AML in
CR3, RR or IF. Pts with unrelated grafts received R-ATG.GVHDprophylaxis consisted of tacrolimus andMMF (Bhatia/Cairo
et al., BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, PFS and OS.
Results: 14 pts, median age: 10.6 yrs (5-18); M:F: 10:4, ALL/AML:
11:3 (9 CR3, 2 RR, 3 IF), 6 related donors, 8 unrelated donors (5
BM/PBSCs, 3 UCB). Median TNC and CD34 dose was 5.04x108/
kg and 5.04x106/kg for BM/PBSCs and 4.0x107/kg and 1.8x105/
kg for UCB. Probabilities of neutrophil and platelet engraftment
and grade II-IV aGVHD were 100%, 91.7% and 51.8%, respec-
tively. All achieved 100% whole blood donor chimerism by day 30.
Day 100 TRM was 0%. CLO dose was tolerable at 52mg/m2/
d x5d and is being used in the phase II setting. No serious adverse
events related to CLO were observed. 2 pts experienced progressive
disease at days 90 and 126. 10 pts are alive in continuous CR at me-
dian 171 days (42-834). Probabilities of 1-yr PFS and OS are 60.2%
(CI95: 24-83%) and 54.0% (CI95: 18-80%), respectively.
Conclusions: Preliminary results suggest this regimen followed by
AlloSCT is safe and well tolerated in CAYA with poor-risk ALL/
AML with CLO dose of 52 mg/m2. Very early results are encourag-
ing with respect to low risk of early leukemic relapse with this
conditioning regimen.89
ALEMTUZUMAB-BASED CONDITIONING PROTOCOLS FOR PAEDIATRIC
MATCHED UNRELATED DONOR TRANSPLANTS FOR SEVERE APLASTIC
ANAEMIA: AN IMPORTANT ALTERNATIVE TO TBI CONTAINING
REGIMENS
Samarasinghe, S.1, Steward, C.2, Hiwarkar, P.1, Bonney, D.3, Keogh, S.2,
Rao, K.1, Amrolia, P.1, Goulden, N.1, Mathew, S.3, Hough, R.4,
Wynn, R.3, Veys, P.1 1Great Ormond Street Hospital, London, United
Kingdom; 2Royal Hospital for Children, Bristol, Bristol, United Kingdom;
3Royal Manchester Children’s Hospital, Manchester, United Kingdom;
4University College Hospital, London, United Kingdom
Background:We analyzed the outcome of 18 consecutive-children
who receivedmatched unrelated donor (MUD) haematopoietic stem
cell transplantation (HCT) for idiopathic severe aplastic anaemia
(SAA) using an Alemtuzumab non-total body irradiation (TBI) based
conditioning regime.
Design and Methods: We conducted a multicentre retrospective
analysis to determine the efficacy of non-TBI, Alemtuzumab-based
conditioning regimens for HCT in idiopathic SAA. The outcomes
analysed were event free survival (EFS), overall survival (OS),
graft-versus-host-disease (GVHD) and viral reactivations.
Results: The median age transplantation was 14.3 years (range 0.7-
19 years). Fourteen of the 18 patients had failed to respond to prior
immunosuppressive therapy. Analysis of 18 patients who received 10
antigen (HLA-A,-B,-C,-DRB1,-DQB1) MUD HCT for idiopathic
SAA between 1999 and 2007 showed an EFS and OS of 100% at
a median follow-up of 3.7 years (range 2.5-10.83 years). Nine of
the 18 patients were full donor chimerae and the other 9 were stable
mixed chimerae (median donor chimerism 100 %; range 95-100 %).
All patients have normal neutrophil and platelets counts and are
transfusion independent. There were no cases of severe acute or ex-
tensive chronic GVHD. Eleven patients remained free of acute
GVHD, 6 developed grade I and only a single patient developed
grade II GVHD (cumulative incidence of grade I-II GVHD 38.8
%). No patient developed grade III-IV acute GVHD. Two patients
developed limited chronic GVHD of the skin (cumulative incidence
of limited chronic GVHD 11.1 %) and no patients developed exten-
sive chronic GVHD.There was a low rate of viral/bacterial morbid-
ity requiring treatment (adenoviral reactivation responding to
cidofovir [1], CMV reactivation responding to donor lymphocyte
infusion [1] and MRSA abscess[1]). There were no cases of EBV
post-transplant lymphoproliferative disease .
Conclusion: These data suggest that Alemtuzumab is sufficiently
immunosuppressive to permit engraftment following MUD HCT
in SAA whilst minimising toxicity and avoiding serious GVHD.
This approach avoids the potential concerns of late carcinogenesis
which accompany the use of TBI in this disease. In the absence of
a matched sibling donor, our data suggests that MUD HCT could
be considered as first line therapy before immune suppression for
